Ironwood Pharmaceuticals Q3 2023 Investor Update

Ironwood Pharmaceuticals presents its third quarter 2023 financial and operational update, highlighting progress on its LINZESS commercial performance and pipeline development. The presentation covers forward-looking strategic priorities, clinical trial progress for product candidates including linaclotide, apraglutide, IW-3300, and CNP-104, and financial guidance for the company.